{"disease":{"id":"amyloidosis-systemic","name":"amyloidosis systemic"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06887283","title":"Essen Amyloidosis Registry","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT03401372","title":"BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Jian Li","has_results":false},{"nct_id":"NCT05951049","title":"A Study of AT-02 in Subjects With Systemic Amyloidosis.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Attralus, Inc.","has_results":false},{"nct_id":"NCT06186167","title":"Amyloidosis Incidence in High-Risk Cardiac Device Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Midwest Heart & Vascular Specialists","has_results":false},{"nct_id":"NCT05521022","title":"Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Attralus, Inc.","has_results":false},{"nct_id":"NCT06192979","title":"Optimize First-line Treatment for AL Amyloidosis With t (11; 14)","phase":"NA","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Jin Lu, MD","has_results":false},{"nct_id":"NCT02994784","title":"Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Boston Medical Center","has_results":true},{"nct_id":"NCT05201911","title":"A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Attralus, Inc.","has_results":false},{"nct_id":"NCT01604122","title":"Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers","phase":"","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05486481","title":"Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Alfred Chung, MD","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}